TrialRheumatology (Oxford, England)2024

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.

Dinesh Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.